Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Every additional dollar spent on newer, less toxic hormonal therapy for breast cancer patients has produced health gains valued at between $27.03 and $36.81.  
  • Use of tamoxifen, a drug used to treat breast cancer, has resulted in a direct cost savings of $41,372 per year of life gained in women 35- to 49-years-old, $68,349…  
  • Investments in cancer care generated $598 billion of additional value for cancer patients diagnosed between 1983 and 1999.  
  • Medicines Prevent Cancer Recurrence: New breast cancer drug greatly reduces recurrence and death (5 to 10 years after diagnosis in postmenopausal women)  
  • The 5-year survival rate for all cancers diagnosed from 1996-2003 is 66%, up from 50% in 1975-1977. This improvement reflects progress in early diagnosis and improvements in treatment.